Cargando…
Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability, and decreased quality of life (QOL). Inhibition of Janus kinase (JAK) signaling ameliorates articular inflammation and joint destruction in animal models of RA, but its effects on beh...
Autores principales: | Tanimoto, Atsuo, Shinozaki, Yuichi, Nozawa, Keisuke, Kimoto, Yukari, Amano, Wataru, Matsuo, Akira, Yamaguchi, Takayuki, Matsushita, Mutsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636776/ https://www.ncbi.nlm.nih.gov/pubmed/26546348 http://dx.doi.org/10.1186/s12891-015-0802-0 |
Ejemplares similares
-
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
por: Tanimoto, Atsuo, et al.
Publicado: (2014) -
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats
por: KATO, Toshinobu, et al.
Publicado: (2018) -
Step-Double-Zone-JTE for SiC Devices with Increased Tolerance to JTE Dose and Surface Charges
por: Huang, Yifei, et al.
Publicado: (2018) -
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2018) -
JTE: first Impact Factor of 2.683
por: Knowles, Jonathan, et al.
Publicado: (2018)